Pilot Phase 2 Study of Intratumoral G100 in Patients With Cutaneous T Cell Lymphoma

What is the purpose of this trial?

The overall goal of this study is to evaluate the safety and immunogenicity of repeat-dose intratumoral G100 administration in patients with Cutaneous T Cell Lymphoma (CTCL) alone (Part 1) and following standard local radiation therapy or topical nitrogen mustard application (Part 2). Plaque, patch, or tumor lesions of CTCL may be injected. Disease will be assessed in all sites, including skin, nodes, and blood.

Yale Cancer Center

Start Date: 03/24/2019

End Date: 12/31/2019

Last Updated: 05/19/2019

Study HIC#: 2000021483

Get Involved

For more information about this study, contact:
Laura Leary

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image


Francine Foss

Principal Investigator